Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell (chimeric antigen receptor therapies), using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | 2026-10-07 14:59:47 | 8.55 | -0.17 | -2.01 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYEL | 0001806952 | Lyell Immunopharma, Inc. | US55083R2031 | — | 833006753 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 201 HASKINS WAY | SOUTH SAN FRANCISCO | CA | 94080 | UNITED STATES | US | 650 695-0677 | 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080 | 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080 | — | Biotechnology | 2018 | — | — | https://lyell.com/ | 129,000,000 | 23,397,000 | 24,505,141 | Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell (chimeric antigen receptor therapies), using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. | 2026-10-01 21:35:36 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 129,000,000 | -177,000,000 | -57.8431 | 23,307,143 | -271,921,725 | -92.1054 |
| 2024 | 306,000,000 | -348,000,000 | -53.211 | 295,228,868 | 41,132,557 | 16.1878 |
| 2023 | 654,000,000 | -446,000,000 | -40.5455 | 254,096,311 | 4,487,064 | 1.7976 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Gary Lee | Chief Scientific Officer | 2025 | 520,015 | 0 | 62,269 | 260,000 | 6,790 | 1,942,621 |
| Lynn Seely | Director, President, Chief Executive Officer | 2025 | 690,173 | 0 | 186,806 | 414,000 | 23,735 | 4,222,265 |
| Stephen Hill | Chief Operating Officer | 2025 | 529,473 | 0 | 62,269 | 291,500 | 9,591 | 2,076,439 |
| Stephen Hill | Chief Operating Officer | 2024 | 516,738 | 0 | 94,800 | 226,400 | 7,304 | 1,342,842 |
| Lynn Seely | Director, President, Chief Executive Officer | 2024 | 675,962 | 0 | 474,000 | 324,000 | 21,414 | 1,495,376 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 161 |
| 2024 | 300 |
| 2023 | 224 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 36,000 | 61,000 | 130,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 36,000 | 61,000 | 130,000 |
| Research And Development Expenses | 158,675,000 | 171,603,000 | 182,945,000 |
| General And Administrative Expenses | 45,135,000 | 52,041,000 | 66,983,000 |
| Operating Expenses | 269,440,000 | 358,816,000 | 247,138,000 |
| Operating Income | -269,404,000 | -358,755,000 | -247,008,000 |
| Net Income | -274,448,000 | -342,994,000 | -234,632,000 |
| Earnings Per Share Basic | -16.06 | -1.31 | -0.93 |
| Earnings Per Share Diluted | -16.06 | -1.31 | -0.93 |
| Weighted Average Shares Outstanding Basic | 17,093,000 | 261,480,000 | 250,983,000 |
| Weighted Average Shares Outstanding Diluted | 17,093,000 | 261,480,000 | 250,983,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 60,181,000 | 105,597,000 | 145,647,000 |
| Marketable Securities Current | 187,039,000 | 264,930,000 | 400,576,000 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 13,719,000 | 9,067,000 | 8,463,000 |
| Total Assets Current | 260,939,000 | 379,594,000 | 554,686,000 |
| Marketable Securities Non Current | 0 | 13,014,000 | 16,506,000 |
| Property Plant And Equipment | 34,771,000 | 48,200,000 | 102,654,000 |
| Other Assets Non Current | 4,886,000 | 4,622,000 | 4,235,000 |
| Total Assets Non Current | 79,113,000 | 111,265,000 | 195,343,000 |
| Total Assets | 340,052,000 | 490,859,000 | 750,029,000 |
| Accounts Payable | 2,893,000 | 5,366,000 | 4,817,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 49,412,000 | 53,788,000 | 34,519,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 517,000 | 3,253,000 | 3,664,000 |
| Total Liabilities Non Current | 42,438,000 | 54,247,000 | 60,558,000 |
| Total Liabilities | 91,850,000 | 108,035,000 | 95,077,000 |
| Common Stock | 2,000 | 29,000 | 25,000 |
| Retained Earnings | -1,619,554,000 | -1,345,106,000 | -1,002,112,000 |
| Accumulated Other Comprehensive Income | 242,000 | 291,000 | -94,000 |
| Total Shareholders Equity | 248,202,000 | 382,824,000 | 654,952,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 11,539,000 | 19,631,000 | 20,250,000 |
| Share Based Compensation Expense | 41,829,000 | 33,144,000 | 47,084,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -2,823,000 | -1,775,000 | -3,125,000 |
| Change In Accounts Payable | -2,339,000 | -3,234,000 | 1,464,000 |
| Change In Other Liabilities | -7,642,000 | -1,250,000 | -719,000 |
| Cash From Operating Activities | -150,024,000 | -162,394,000 | -163,694,000 |
| Purchases Of Marketable Securities | 278,899,000 | 394,707,000 | 476,880,000 |
| Sales Of Marketable Securities | 374,684,000 | 548,941,000 | 663,614,000 |
| Acquisition Of Property Plant And Equipment | 780,000 | 464,000 | 2,686,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 54,097,000 | 122,424,000 | 184,048,000 |
| Tax Withholding For Share Based Compensation | 1,000 | 76,000 | 457,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 50,000,000 | 1,248,000 | 1,894,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 50,406,000 | 1,326,000 | 1,743,000 |
| Change In Cash | -45,521,000 | -38,644,000 | 22,097,000 |
| Cash At End Of Period | 60,181,000 | 105,597,000 | 145,647,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -16.06 | -1.31 | -0.93 |
| Price To Earnings Ratio | -1.9166 | -9.771 | -41.7204 |
| Earnings Growth Rate | 1,125.9542 | 40.8602 | 25.6757 |
| Price Earnings To Growth Ratio | -0.0017 | -0.2391 | -1.6249 |
| Book Value Per Share | 14.5207 | 1.4641 | 2.6095 |
| Price To Book Ratio | 2.1197 | 8.7428 | 14.8685 |
| Ebitda | -262,909,000 | -323,363,000 | -214,382,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -1,890,000 | -34,823,000 | -119,000 |
| Free Cash Flow | -148,134,000 | -127,571,000 | -163,575,000 |
| Return On Equity | -1.1057 | -0.896 | -0.3582 |
| One Year Beta | 1.249 | 2.1705 | 2.1384 |
| Three Year Beta | 1.6542 | 1.8245 | 1.6051 |
| Five Year Beta | 1.567 | 1.6841 | 1.6051 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Aguirre Jarrad Mattieu | Chief Medical Officer | 2026-09-10 | 47,500 | A | 47,500 |
| Shook David | Chief Medical Officer | 2026-09-10 | 500 | D | 20,423 |
| Seely Lynn | Director, President and CEO | 2026-08-21 | 9,589 | D | 63,899 |
| Lee Gary K. | Chief Scientific Officer | 2026-08-21 | 1,457 | D | 16,220 |
| Hill Stephen J. | Chief Operating Officer | 2026-08-21 | 989 | D | 16,816 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| STATE STREET CORP | 2026-06-30 | 2,603,774 | 185,322 | 14.05 |
| CITADEL ADVISORS LLC | 2026-06-30 | 251,495 | 17,900 | 14.05 |
| CITADEL ADVISORS LLC | 2026-06-30 | 262,665 | 18,695 | 14.05 |
| CITADEL ADVISORS LLC | 2026-06-30 | 238,850 | 17,000 | 14.05 |
| Cornerstone Financial Management LLC | 2026-06-30 | 646 | 46 | 14.0435 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 898 | 11,620.12 | 0.0014 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 9,029 | 116,835.26 | 0.0042 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 4,474 | 57,893.56 | 0.0039 |
| Advisors' Inner Circle Fund III | 2026-07-31 | I Shares | KCXIX | 111 | 1,436.34 | 0.0004 |
| PRINCIPAL FUNDS, INC. | 2026-07-31 | R-6 | PSMVX | 770 | 9,963.8 | 0.0008 |